Clinical Trials Logo
  1. Home
  2. Palmoplantar Pustulosis
  3. NCT04459507

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan — ProPuP  

Palmoplantar Pustulosis Clinical Trial

Official title:
Registry of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

Clinical Trial Summary

The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.

Clinical Trial Description

This is a retrospective study where the historical data on PPP therapy will also be used prior to Visit 1 (baseline). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04459507
Study type Observational
Source Janssen Pharmaceutical K.K.
Contact
Status Active, not recruiting
Phase
Start date March 22, 2021
Completion date September 30, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04493424 - A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab Phase 2
Recruiting NCT05994976 - Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Completed NCT04572997 - Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) Phase 2
Completed NCT03633396 - A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis Phase 2
Active, not recruiting NCT05174065 - Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Phase 3
Completed NCT01780857 - Immune Signature of Palmoplantar Pustulosis N/A
Completed NCT03972280 - Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Phase 1
Completed NCT01794117 - Anakinra for Inflammatory Pustular Skin Diseases Phase 2
Recruiting NCT05710185 - Deucravacitinib for the Treatment of Palmoplantar Pustulosis Phase 4
Terminated NCT05194839 - A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) Phase 2
Active, not recruiting NCT04566471 - Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
Completed NCT03988335 - A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) Phase 2
Completed NCT02641730 - An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis Phase 3
Completed NCT04061252 - A Study of KHK4827 in Subjects With Palmoplantar Pustulosis Phase 3